Receptor Tyrosine Kinases in Cancer
Receptor tyrosine kinases (RTKs) play a critical role in a variety of cellular processes including growth, differentiation, motility, and metabolism. RTKs are frequently overexpressed and their aberrant signalling is associated with various diseases including cancer. Thus, RTKs have become one of th...
Na minha lista:
| Autor Corporativo: | |
|---|---|
| Outros Autores: | , , |
| Formato: | Recurso Eletrônico livro eletrônico |
| Idioma: | inglês |
| Publicado em: |
Cham :
Springer Nature Switzerland : Imprint: Springer,
2025.
|
| Edição: | 1st ed. 2025. |
| coleção: | Cancer Drug Discovery and Development,
|
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1007/978-3-031-93894-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-031-93894-8 | ||
| 003 | DE-He213 | ||
| 005 | 20260810165633.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 250726s2025 sz | o |||| 0|eng d | ||
| 020 | |a 9783031938948 |9 978-3-031-93894-8 | ||
| 024 | 7 | |a 10.1007/978-3-031-93894-8 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Receptor Tyrosine Kinases in Cancer |h [electronic resource] / |c edited by Akash Sabarwal, Saba Tabasum, Soumitro Pal. |
| 250 | |a 1st ed. 2025. | ||
| 264 | 1 | |a Cham : |b Springer Nature Switzerland : |b Imprint: Springer, |c 2025. | |
| 300 | |a 1 online resource (XXII, 365 p. 37 illus.). | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b PDF/UA-1 |2 onix | |
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of color is not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background color |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 505 | 0 | |a An Introduction to Receptor Tyrosine Kinases Signal Transduction and Cancer Progression -- Tyrosine Kinases and Inflammatory Signaling in Cancer -- Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy -- AXL and its Role in Cell Migration and Epithelial to Mesenchymal Transition -- VEGFR and its Role in Tumor Angiogenesis -- c-MET Therapeutic Target and Biomarker in Cancer -- Receptor Tyrosine Kinase signaling and Mitochondria -- Therapeutic Potential of Targeting Immune Checkpoints Along with RTKs -- Combination therapies involving RTK inhibitors -- RTKs as a Therapeutic Target by Natural Compounds in Cancer Treatment. | |
| 520 | |a Receptor tyrosine kinases (RTKs) play a critical role in a variety of cellular processes including growth, differentiation, motility, and metabolism. RTKs are frequently overexpressed and their aberrant signalling is associated with various diseases including cancer. Thus, RTKs have become one of the most important druggable targets for the treatment of cancer. The emergence of small kinase inhibitors in cancer treatment offers a strategic approach to the management of cancer that surpasses the efficacy of traditional drugs. Understanding RTK signaling mechanisms is of paramount importance, especially as the US FDA and other global regulatory agencies have approved several small-molecule tyrosine inhibitors. Moreover, pharmaceutical companies are actively developing new compounds for the treatment of various malignancies. This comprehensive book addresses a timely need by presenting the latest advances and cutting-edge insights into RTKs in cancer research. The chapters provide overviews and recent developments regarding the roles of key RTKs —such as, c-Met, AXL, VEGFR, EGFR, among others—in pro-tumorigenic signaling, therapeutic resistance, and targeted inhibition across different cancer types. This volume serves as an essential resource for researchers and students seeking to deepen their understanding of this rapidly evolving field. . | ||
| 532 | 8 | |a Accessibility summary: This PDF has been created in accordance with the PDF/UA-1 standard to enhance accessibility, including screen reader support, described non-text content (images, graphs), bookmarks for easy navigation, keyboard-friendly links and forms and searchable, selectable text. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. Please note that a more accessible version of this eBook is available as ePub. | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 588 | |a Print version record. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Molecular biology. | |
| 650 | 0 | |a Biophysics. | |
| 650 | 0 | |a Cell interaction. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Molecular Biology. |
| 650 | 2 | 4 | |a Mechanobiological Cell Signaling. |
| 700 | 1 | |a Sabarwal, Akash. |e editor. |0 (orcid)0000-0003-1760-4903 |1 https://orcid.org/0000-0003-1760-4903 |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Tabasum, Saba. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Pal, Soumitro. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031938931 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031938955 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031938962 |
| 830 | 0 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-031-93894-8 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 912 | |a ZDB-2-237 | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||
| 950 | |a Focus Bundle Biomedical and Human Health Sciences (SpringerNature-85407) | ||